ArticleBMC medical genomics2026
Evaluation and management of DMD gene copy number variations detected by prenatal SNP-array testing.
Article in BMC medical genomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
objectiveThis study aims to evaluate the clinical management of incidental findings of copy number variations (CNVs) in the DMD gene detected through prenatal single nucleotide polymorphism array (SNP-array).
methodsPrenatal SNP-array testing was performed on samples exhibiting CNVs in the DMD locus, followed by parental analysis using the same technique. Additionally, multiplex ligation-dependent probe amplification (MLPA) testing was conducted on prenatal cases and their parents. Pregnancy outcomes were documented, and postnatal follow-up was conducted.
resultsSNP-array analysis identified copy number variations at Xp21 affecting either the entire DMD gene or only a portion of it in 14 fetuses. In 11 cases, MLPA testing confirmed the presence of deletions or duplications detected by the SNP-array.
conclusionHigh-density SNP-array platforms with low reporting thresholds may incidentally detect a subset of exon-level copy number variations involving the DMD gene during routine prenatal testing and thereby contribute to early recognition of potential dystrophinopathy-related variants. Suspected DMD-related CNVs, especially exon-level alterations, require confirmation by targeted assays such as MLPA or next-generation sequencing, together with cautious clinical interpretation. Assessing the pathogenicity of prenatally detected DMD copy number variations remains challenging, particularly for duplications, which require careful evaluation. Furthermore, the sequential, time-intensive nature of confirmatory and familial studies often limits definitive risk assessment within the prenatal decision-making window, and introduces broader familial implications that must be navigated through careful, multidisciplinary counseling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.